Lighting up heart disease without antibodies: Researchers design low-cost blood test for resource-poor clinics
· Medical Xpressby Ben-Gurion University of the Negev
edited by Gaby Clark, reviewed by Robert Egan
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
Rheumatic heart disease (RHD) claims hundreds of thousands of lives each year, devastating children and young adults in low- and middle-income countries where access to specialized ultrasound equipment and refrigerated testing labs is virtually nonexistent. Inexpensive penicillin could stop the progressive valve damage if the disease is detected early, yet millions remain undiagnosed until irreversible heart failure sets in.
Now, researchers from Ben-Gurion University of the Negev (BGU) have engineered a synthetic, antibody-free diagnostic probe that detects cardiac inflammatory biomarkers in blood without requiring cold-chain refrigeration or complex laboratory machinery. The study, published in ACS Sensors, lays the groundwork for affordable, rapid point-of-care screening in rural and underserved communities.
The research was led by professor Ayelet David alongside Ilana Teboul, Naama Shlush, Maya Droby and Dr. Yvonne Ventura from BGU's Department of Clinical Biochemistry and Pharmacology, in collaboration with the late professor Robert A. Levine of Massachusetts General Hospital and Harvard Medical School.
The diagnostic bottleneck in global health
Triggered by untreated group A streptococcal throat infections, rheumatic fever causes chronic inflammation that progressively thickens, scars and calcifies cardiac valves. Although regular antibiotic injections can prevent recurrent damage, identifying patients before heart valves are destroyed currently demands echocardiography machines or complex antibody-based blood assays such as ELISA.
Standard ELISA testing relies on biological antibodies that are expensive to manufacture, vulnerable to heat degradation and dependent on multistep processing. In low-resource clinics lacking continuous refrigeration or automated equipment, widespread immunoassay screening is virtually impossible.
A 'light-up' molecular tripwire
To bypass biological antibodies entirely, the BGU team built a fully synthetic, polymer-based sensor using an HPMA backbone functionalized with specific peptide ligands and near-infrared fluorescent dyes. The probe is engineered to function like an optical switch:
- Built-in optical silencing: When floating freely, the polymer remains tightly clustered, bringing the dye molecules into close proximity so they naturally absorb and quench each other's light.
- Biomarker-activated signal: When the synthetic peptides encounter E-selectin—a key adhesion molecule shed into the blood during active valvular inflammation—the polymer uncoils, pulling the dyes apart and producing a sharp "turn-on" fluorescent glow.
- Direct blood sensing: In laboratory trials, the probe successfully captured and quantified E-selectin directly in complex serum samples, producing a clear, dose-dependent optical readout on standard microplate readers.
Breaking the cold-chain barrier
"Current diagnostics depend heavily on delicate animal-derived antibodies that spoil if they aren't kept on ice," says lead researcher David. "By replacing antibodies with robust synthetic polymers and peptides, we have created a platform that is inherently stable, significantly cheaper to manufacture and resilient to ambient temperatures. It is built specifically to survive real-world conditions where cold-chain logistics simply don't exist."
No established blood biomarker is currently available for diagnosing RHD. A panel of markers is therefore needed to distinguish RHD patients from patients with non-rheumatic valvular disease or other inflammatory conditions.
By simply swapping the targeting peptides, the same polymer backbone can be adapted to detect biomarkers for many vascular and inflammatory diseases. While current sensitivity operates in the microgram range and further optimization is underway to detect minute nanogram-level concentrations in early-stage patients, the modular design provides an immediate translational platform.
Publication details
Ilana Teboul et al., Polymeric Probe for Sensitive Diagnosis of Serum Endothelial Cell Adhesion Molecules in Rheumatic Heart Disease, ACS Sensors (2026). DOI: 10.1021/acssensors.6c03085
Journal information: ACS Sensors
Key medical concepts
Clinical categories
CardiologyLaboratory medicine Provided by Ben-Gurion University of the Negev Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Lighting up heart disease without antibodies: Researchers design low-cost blood test for resource-poor clinics (2026, November 11) retrieved 12 November 2026 from https://medicalxpress.com/news/2026-11-heart-disease-antibodies-blood-resource.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.